pharmaphorum November 12, 2024
AstraZeneca plans to invest a whopping $3.5 billion to expand its R&D and manufacturing operations in the US by 2026, as part of a drive to raise its revenues to $80 billion by the end of the decade.
The programme – part of the pharma group’s Ambition 2030 effort – will include the construction of a new R&D centre at Kendall Square in the heart of the biopharma hub in Cambridge, Massachusetts, and a biologics manufacturing facility in Maryland.
There will also be expansion of cell therapy manufacturing capacity on “the West and East coasts,” as well as specialty manufacturing in Texas, according to AZ, which said $2 billion of the investment is earmarked for the creation of more than...
Today's Sponsors
Today's Sponsor